Steroidogenesis

Overview

Steroidogenesis is the process by which cholesterol is converted into the five major classes of steroid hormones: glucocorticoids, mineralocorticoids, androgens, estrogens, and progestogens. A distinct but related pathway produces vitamin D. Steroidogenesis occurs primarily in the adrenal cortex (producing cortisol, aldosterone, and androgen precursors), testis (testosterone), ovary (estradiol and progesterone), placenta (progesterone, estrogens), and — at much smaller scales — in brain, adipose tissue, and other sites.

Steroidogenesis is orchestrated by tissue-specific expression of a common core of cytochrome P450 and hydroxysteroid dehydrogenase enzymes. Each tissue expresses a subset tailored to produce specific hormones. Shared with all steroidogenic tissues is the first committed step: conversion of cholesterol to pregnenolone by the side-chain cleavage enzyme CYP11A1 inside mitochondria. Downstream modifications diverge across tissues.

Steroid hormones regulate fundamental physiology: metabolism and stress response (cortisol), salt and water balance (aldosterone), sexual development and reproductive function (androgens, estrogens, progestogens), and bone and mineral homeostasis (vitamin D). Steroidogenic disorders — congenital adrenal hyperplasia, Addison disease, hyperaldosteronism, polycystic ovary syndrome, adrenal tumors — have substantial clinical impact.

Mechanism / Process

1. Cholesterol delivery. Steroidogenic cells acquire cholesterol from circulating LDL (via LDL receptor), HDL (via SR-BI), and de novo cholesterol synthesis. Cholesterol is stored in cytoplasmic droplets as cholesteryl esters; hormone-sensitive lipase mobilizes it on demand.

2. Mitochondrial import. The steroidogenic acute regulatory protein (StAR) ferries cholesterol from the outer to the inner mitochondrial membrane. This is the rate-limiting step and the primary target of acute hormonal stimulation (ACTH, LH).

3. Side-chain cleavage. CYP11A1 (P450scc) on the inner mitochondrial membrane cleaves the side chain of cholesterol to produce pregnenolone.

4. Tissue-specific pathways. Pregnenolone is funneled through distinct enzymatic pathways depending on tissue:

   • Adrenal zona glomerulosa: leads to aldosterone via CYP11B2.
   • Adrenal zona fasciculata: leads to cortisol via CYP17 (17-alpha-hydroxylase), CYP21A2 (21-hydroxylase), CYP11B1.
   • Adrenal zona reticularis and gonads: produce androgens (DHEA, androstenedione, testosterone) via CYP17 17,20-lyase activity, HSD3B2, HSD17B3.
   • Ovary and placenta: aromatize androgens to estrogens via CYP19 (aromatase).

5. Modifications. Hydroxysteroid dehydrogenases oxidize and reduce hydroxyl groups, interconverting active and less-active steroids (e.g., 11-beta-HSD1 regenerates cortisol from cortisone in liver and adipose).

6. Secretion. Steroids diffuse out of cells (they are not stored in granules due to lipid solubility) and travel in plasma bound to carrier proteins (cortisol-binding globulin, sex hormone-binding globulin, albumin).

7. Regulation. ACTH activates adrenal steroidogenesis via cAMP, increasing StAR and enzyme expression. LH activates testicular and ovarian steroidogenesis similarly. FSH supports aromatase expression in granulosa cells. Angiotensin II activates aldosterone synthesis.

Key Players / Molecular Components

• StAR. Rate-limiting cholesterol transport.
• CYP enzymes. CYP11A1, CYP17A1, CYP21A2, CYP11B1, CYP11B2, CYP19A1 (aromatase).
• HSD enzymes. HSD3B1/2, HSD17B1/3, HSD11B1/2.
• Transcription factors. SF-1 (NR5A1) and DAX1 regulate steroidogenic gene expression.
• Hormonal regulators. ACTH, LH, FSH, angiotensin II.

Clinical Relevance / Therapeutic Targeting

Steroidogenic disorders are common and clinically important. Congenital adrenal hyperplasia (most commonly 21-hydroxylase deficiency) impairs cortisol and aldosterone synthesis, causing salt wasting and virilization. Addison disease (primary adrenal insufficiency) requires lifelong glucocorticoid and mineralocorticoid replacement. Inhibitors of steroidogenesis treat Cushing syndrome (metyrapone, ketoconazole, osilodrostat, levoketoconazole, etomidate), hyperaldosteronism, and hormone-dependent cancers. Aromatase inhibitors (anastrozole, letrozole, exemestane) treat estrogen receptor-positive breast cancer. Abiraterone inhibits CYP17A1 for prostate cancer. 5-alpha-reductase inhibitors (finasteride, dutasteride) treat BPH and male pattern hair loss.

Peptides That Target This Pathway

• ACTH — principal stimulator of adrenal steroidogenesis.
• LH — stimulates gonadal steroidogenesis.
• FSH — supports ovarian aromatase expression.
• GnRH analogs — modulate downstream LH/FSH and gonadal steroid output.
• Angiotensin II — stimulates aldosterone synthesis.
• Kisspeptin — regulates GnRH and downstream steroidogenesis.
• CRH — drives ACTH release, initiating adrenal steroidogenesis.

Related Topics

• Cholesterol Synthesis
• HPA Axis
• HPG Axis
• Vitamin D Signaling
• Bile Acid Synthesis